RVU Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Ryvu Therapeutics SA - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 51.9 PLN 0.78% Market Closed
Market Cap: 1.2B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 84.25 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
69.19 PLN
33% Upside
Average
Price Target
84.25 PLN
62% Upside
Highest
Price Target
104.27 PLN
101% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
QGEN
Qiagen NV
16% Upside
QSI
Quantum-Si Inc
208% Upside
SKAN
SKAN Group AG
26% Upside
SHC
Sotera Health Co
9% Upside
301230
PharmaResources Shanghai Co Ltd
96% Upside
PIQ
Proteomics International Laboratories Ltd
12% Upside
688114
MGI Tech Co Ltd
83% Upside
300030
Improve Medical Instruments Co Ltd
232% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 2 years is 189%.

2%
Past Growth
189%
Estimated Growth
Estimates Accuracy
-36%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
84.25 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 84.25 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
189%

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 2 years is 189%.

Back to Top